Dr. Clay Siegall is a co-founder of Seattle Genetics, a scientific company doing major research and drug development for targeted cancer therapies. Siegall started the company in 1998 with his partner Mark Okada. He is passionate about finding innovative cancer treatments that can help patients live longer, higher quality lives. The company received FDA approval in 2011, or one of its first antibody drug conjugates, ADCETRIS. The company formed a partnership with Takeda Pharmaceutical Company, for distribution of the drug. It is now approved in more than 65 countries around the world.
Seattle Genetics, has entered licensing agreements for its ADC technology with Pfizer, GlaxoSmithKline and Genentech. These agreements have generated more than $350 million for the company to date. Currently there are over 20 ADCs in clinical development and trials. Siegall has been a major force in raising capital and securing public financing for the company. Seattle Genetics have their initial public offering in 2001.
Dr. Clay Siegall has always had an interest in working on cures for cancer. Prior to joining Seattle Genetics, he worked with Bristol-Myers Squibb in their research Institute, from 1991 to 1997. He worked with the National Cancer Institute and the National Institutes of Health from 1988 to 1991. He is on the Board of Directors for several companies including Alder Biopharmaceuticals. Ultragenyx Pharmaceutical and he is on the Washington Roundtable.
Dr. Siegall received his Bachelor’s Degree in zoology from the University of Maryland. He earned his pH D in Genetics from George Washington University. His mission is to improve the lives of people with cancer through new antibody-based therapies. The company’s goals are carried out with honesty and integrity and respect. They strive for scientific excellence in everything they do.